1	DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy:
2	a meta-analysis and systematic review
3	
4	Zoe Phan ^{1,2} , Caroline E. Ford ³ , C. Elizabeth Caldon ^{1,2#}
5	
6	1. The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, NSW,
7	2010, Australia
8	2. St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales,
9	Sydney, NSW, 2052, Australia
10	3. School of Clinical Medicine, Faculty of Medicine and Health, University of New South
11	Wales, Sydney, NSW, 2052, Australia
12	# Corresponding author: l.caldon@garvan.org.au
13	
14	
15	KEYWORDS: PARP inhibitor, homologous recombination deficiency, chemotherapy,
16	combination therapy, BRCA1/2, SFLN11, survival, DNA repair
17	WORD NUMBER: 5947
18	ACKNOWLEDGEMENTS: We thank Dr Mark Donoghoe of Stats Central, Mark
19	Wainwright Analytical Centre, UNSW Sydney, for assistance with data extraction methods for
20	the meta-analysis. This research was generously supported by the Dr Lee MacCormick
21	Edwards Charitable Foundation. C.E.C. is supported by a Cancer Institute NSW Career
22	Development Fellowship (CDF1071).
23	

24 ABSTRACT

25 Purpose

The addition of PARP inhibitors to chemotherapy has been assessed in ~80 clinical trials across 26 27 multiple malignancies, on the premise that PARP inhibitors will increase chemotherapy 28 effectiveness regardless of whether cancers have underlying disruption of DNA repair 29 pathways. Consequently, the majority of combination therapy trials have been performed on 30 patients without biomarker selection, despite the use of homologous recombination deficiency 31 to dictate use of PARP inhibitors in the maintenance setting. An unresolved question is whether 32 biomarkers are needed to identify patients who respond to combination PARP inhibitors and 33 chemotherapy.

34

35 Methods

A systematic literature review identified studies using PARP inhibitors in combination with chemotherapy versus chemotherapy alone, where the study included a biomarker of DNA repair function (*BRCA1*, *BRCA2*, BRCAPRO, ATM, ERCC1, SFLN11). Hazard ratios (HR) were pooled in a meta-analysis using generic inverse-variance and fixed or random effects modelling. Subgroup analyses were conducted on biomarker selection and type of malignancy.

42 **Results**

Nine studies comprising 2,084 patients met the inclusion criteria. Progression-free survival (PFS) was significantly better in patients with a DNA repair biomarker (HR 0.52, 95% confidence interval (CI) 0.43-0.63; p < 0.00001), but there was no benefit in patients who lacked a biomarker (HR 0.94, 95% CI 0.82–1.08; p = 0.38). Subgroup analysis showed that *BRCA* mutation and SFLN11 biomarkers could predict benefit, and biomarker-driven benefit

48 occurred in ovarian, breast and small cell lung cancers. The addition of PARP inhibitors was
49 associated with increased grade 3/4 side effects, and particularly neutropenia.

50

51 Conclusions

- 52 Combination therapy only increases PFS in patients with identifiable DNA repair biomarkers.
- 53 This indicates that PARP inhibitors do not sensitise patients to chemotherapy treatment, except
- 54 where their cancer has a homologous recombination defect, or an alternative biomarker of
- 55 altered DNA repair. While effective in patients with DNA repair biomarkers, there is a risk of
- 56 high-grade haematological side-effects with the use of combination therapy. Thus, the benefit
- 57 in PFS from combination therapy must be weighed against potential adverse effects, as
- 58 individual arms of treatment can also confer benefit.

59 GRAPHICAL ABSTRACT6061

01

62

PARP INHIBITORS ONLY SHOW EVIDENCE OF SYNERGY WITH CHEMOTHERAPY IN CANCERS WITH A DNA REPAIR BIOMARKER



64 INTRODUCTION

65 Cancer places an enormous burden on our healthcare system as the leading cause of death worldwide, accounting for nearly 10 million deaths in 2020 [1]. Targeted therapies and 66 67 personalised medicines are now demonstrating significant benefit in reducing cancer-68 associated mortality [2]. Poly (ADP-ribose) polymerase (PARP)-inhibitors were introduced as 69 a targeted therapy in 2014, with initial approvals to treat cancers that had defects in homologous 70 recombination, such as mutations in the genes BRCA1 and BRCA2. Alterations to homologous 71 recombination-related genes lead to a homologous recombination deficiency where cells are 72 unable to accurately repair DNA breaks and become overly reliant on other DNA repair 73 pathways, and particularly PARP-mediated repair. PARP inhibitors have also been investigated 74 in cancers with alterations in other DNA repair related genes [3]. When PARP is inhibited or 75 trapped on DNA in a cell with DNA repair deficiency, these cells rely on more error-prone 76 pathways of repair, and this leads to the accumulation of DNA damage and subsequent cell 77 death (Figure 1A).



Figure 1. Schematic of how chemotherapy could potentiate PARP inhibition. In Panel A, 79 80 a cancer cell with homologous recombination deficiency (HRD) is sensitive to PARP 81 inhibitors because cells are unable to properly repair low level DNA damage, leading to 82 cancer cell death. Low level DNA damage is constantly generated by common 83 environmental exposures (UV, radiation) and endogenous DNA damage from oxidation 84 and DNA metabolism [4]. In Panel B, a cell with intact homologous recombination (HR) 85 is able to repair low level damage through homologous recombination, even in the 86 presence of PARP inhibitors. In Panel C, a cell with intact homologous recombination 87 may be sensitised to chemotherapy by inhibiting DNA repair with PARP inhibitors.

88

89 Four PARP inhibitors are approved for clinical use as monotherapies: olaparib, rucaparib, 90 niraparib and talazoparib. Olaparib was first approved as a maintenance therapy for patients 91 with platinum-sensitive recurrent germline BRCA-mutated ovarian cancer who had a complete 92 or partial response to platinum-based chemotherapy [5]. Olaparib has since been approved for 93 HER2-negative, germline BRCA-mutated breast cancer, and a subset of pancreatic cancer 94 patients [6, 7]. In 2016, rucaparib was approved as a monotherapy for patients with advanced 95 ovarian cancer with either somatic or germline BRCA mutations [8]. In 2018, talazoparib was 96 approved for the treatment of deleterious germline BRCA-mutated, HER2-negative metastatic 97 breast cancer [9]. Niraparib has demonstrated benefit in ovarian cancer patients who have 98 previously responded to platinum chemotherapy, regardless of their homologous 99 recombination deficiency status [8, 10, 11] which has led to its approval in the maintenance 100 setting for newly diagnosed and recurrent ovarian cancers with platinum response. Additional 101 PARP inhibitors, such as veliparib, are currently being evaluated in clinical trials [12-16].

103 A critical aspect of PARP inhibitor usage is to accurately identify patients that will benefit from 104 these targeted therapies. The most common predictive biomarkers to indicate PARP inhibitor 105 sensitivity are mutations in the genes, BRCA1 and BRCA2, which are essential in maintaining 106 genomic integrity. Identifying pathogenic *BRCA1/BRCA2* mutations can be further refined by 107 using genetic tests such as Myriad BRACAnalysis CDx, to determine germline BRCA1/BRCA2 108 mutations, or statistical models such as BRCAPRO, which incorporate family and individual 109 history of cancer diagnoses. Homologous recombination deficiency can also be driven by other 110 genomic changes including BRCA1 methylation, or PALB2/RAD51C/RAD51D mutations [17]. 111 However, these aberrations are not yet used clinically to identify patients for treatment with 112 PARP inhibitors. The presence of these mutations can give rise to characteristic genomic 113 rearrangements indicative of the loss of homologous recombination, which is often termed 114 "genomic scarring". Genomic scars include loss of heterozygosity, large-scale translocations 115 and telomeric allelic imbalance. Next-generation sequencing-based assays such as myChoice 116 CDx can be used as an alternative or adjunct test to detect these genomic rearrangements and 117 identify homologous recombination deficient (HRD) patients within the clinic, and this 118 approach is commonly referred to as 'HRD-score' (Table 1).

119

New markers of altered DNA repair potential are also emerging (e.g. ATM, ERCC1, SLFN11) 120 121 and being assessed pre-clinically and in clinical trials. ATM is a key activator of the DNA 122 damage response to double-strand breaks and in pre-clinical models, loss/depletion of ATM 123 was shown to increase sensitivity of cells to PARP inhibitors in gastric, colorectal, lung and 124 pancreatic cancer [18]. Clinical trials are now assessing the benefit of PARP inhibitors in ATM-125 deficient prostate and gastric cancer patients [19, 20]. ERCC1 is a key mediator of nucleotide 126 excision DNA repair, and it has been proposed that PARP inhibition increases sensitivity of 127 ERCC1-low non-small cell lung cancer cells to cisplatin [21]. SLFN11 is implicated in

replication fork stress and has been studied in several pre-clinical models of small cell lung cancer where high SLFN11 expression strongly predicted cisplatin and PARP inhibitor response [22-24].

131

Since the realisation of the clinical benefit of PARP inhibitors, a significant effort had been made to expand their use to treat cancers without underlying DNA repair defects. Thus, a large body of research has investigated whether there is synergy between PARP inhibitors and other therapies, including chemotherapies. The premise for synergy is that excessive DNA damage from chemotherapy will create too many DNA breaks and adducts to be repaired when PARP is simultaneously inhibited, resulting in lethality (**Figure 1B**). This is hypothesised to occur irrespective of defects in DNA repair [25-27].

139

140 Multiple preclinical in vitro and in vivo studies have demonstrated that synergy between PARP 141 inhibitors and chemotherapies can occur in the absence of identifiable DNA repair defects. 142 Several studies that combine PARP inhibitors with DNA alkylating agent temozolimide (TMZ) 143 have reported synergy: with niraparib across in vitro wildtype pheochromocytoma models [28], 144 with olaparib across in vitro and in vivo xenograft models of chordoma [29], with niraparib for 145 multiple myeloma [30], with veliparib in melanoma and glioma mouse models [31], and PARP 146 inhibitor GPI 15427 in combination with TMZ and CPT-11 colon cancer cell line models and xenografts [32]. The addition of TMZ to PARP inhibitors is believed to increase cell death not 147 148 only by aggravating DNA damage, but also via increased PARP trapping [27, 33].

149

Topoisomerase I inhibitors (irinotecan and its active metabolite, SN-38) have also been
combined with PARP inhibitors to demonstrate anti-tumour effects in preclinical models.
Examples include with PARP inhibitors in *BRCA1/2* wildtype *in vitro* and xenograft models of

triple negative breast cancer [34], with niraparib across *in vivo* and *in vitro* models of colorectal cancer without microsatellite instability [35], with veliparib in *in vitro* colon cancer models [36], with olaparib in colon cancer cell lines *in vitro* and in xenografts [37], and with PARP inhibitors in mouse leukemic cells [38].

157

158 Anti-tumour effects have also been elicited with combination of doxorubicin and olaparib in 159 2D and 3D ovarian cancer models [39], and between olaparib and a range of chemotherapies 160 in oesophageal squamous cell carcinoma cell lines [40]. Most recently, paclitaxel was 161 suggested to sensitise homologous recombination-proficient ovarian cancer cells to olaparib 162 [41]. By contrast Murai and colleagues reported that PARP inhibitors have little combinatorial 163 effect with cisplatin, but they synergise with camptothecin [33]. Studies of triplet treatment 164 with chemotherapy, irradiation and PARP inhibition has also shown promise in colorectal 165 cancer models [42].

166

167 This significant body of pre-clinical data has led to ~80 clinical trials to test PARP inhibitor 168 and chemotherapy combinations (see Supplementary Table 1) [43]. An assessment of these 169 trials shows that combination PARP inhibitors and chemotherapy has primarily been assessed on unselected patient populations (Figure 2). In these trials only 22/79 (28%) included DNA 170 171 repair function as an inclusion criterion for patients entering the trial. Thus, the majority of 172 trials (72%; 57/79) do not require patients to have tumours with altered DNA repair status. 173 19/57 trials specify secondary analyses relating to DNA repair markers, however since these 174 trials mostly occur across cancer types with low penetrance of DNA repair defects, these may 175 not have accrued any cases with DNA repair alterations, or may not be sufficiently powered to 176 draw any conclusions. Of the fourteen clinical trials that are actively recruiting or preparing to 177 recruit patients, nine do not use DNA damage biomarkers as inclusion criteria, including trials

on gastric and small cell lung cancer (NCT05411679), relapsed paediatric acute myeloid
leukemia (NCT05101551), uterine leiomyosarcoma (NCT05432791), pancreatic cancer
(NCT05257993), advanced stage rare cancers (NCT05142241), leiomyosarcoma and renal cell
cancers (NCT04603365), breast cancer (NCT03150576), small cell cancers (NCT04209595),
and ewing sarcoma and rhabdomyosarcoma (NCT01858168).

183

Outcomes of combination trials have now been reported, allowing an assessment of whether chemotherapy plus PARP inhibitor treatment generally improves outcome for patients. Importantly there are now sufficient studies to assess whether any improvement in survival is dependent on the presence of a DNA repair biomarker. Here, we provide the first synthesised analysis of the benefit of PARP inhibitors plus chemotherapies across multiple malignancies. Our study addresses whether the success of combination therapies in pre-clinical models without DNA repair vulnerabilities translates to an improvement in outcome of all patients.



- 192 Figure 2. Number of combination PARP inhibitor and chemotherapy clinical trials
- 193 selecting for DNA repair biomarker status and their year of initiation. 22/79 (28%)
- 194 clinical trials included DNA repair biomarkers as a selection criterion for patients
- 195 entering the trial and 57/79 (72%) clinical trials did not include DNA repair biomarkers
- 196 as a selection criterion. Search of these clinical trials was completed in August 2022. Full
- 197 details of trials are shown in Supplementary Table 1.

198 **METHODS**

199 **PRISMA statement**

200 This meta-analysis was performed following the Preferred Reporting Items for Systematic

- 201 reviews and Meta-analysis (PRISMA) statement.
- 202

203 Search strategies

204 In October 2021, a systematic literature search of all English-language, phase II/III randomised 205 controlled trials was conducted on PubMed, EMBASE and Conference Proceedings Citation 206 Index - Science, with additional searches performed in August 2022. The website 207 ClinicalTrials.gov was searched for additional clinical trials. The search terms used were 208 "PARP-inhibitor", "chemotherapy" and "combination". To identify only randomised 209 controlled trials during the search, we used the format of 'Cochrane Highly Sensitive Search 210 Strategy' [44]. The reference lists of identified articles were also interrogated to further detect 211 any relevant studies.

212

213 Eligibility criteria

For progression-free survival (PFS), the inclusion criteria for the meta-analyses were: 1) phase II/III randomised controlled trials, 2) patients with cancer of any origin, 3) available biomarker data 4), patients were treated with PARP inhibitors in combination with chemotherapy in the experimental arm and chemotherapy plus placebo in the control arm, and 5) available information on PFS.

219

Exclusion criteria for PFS was studies where data could not be extracted on specified outcomesor DNA repair biomarkers.

For the meta-analyses of adverse effects, the inclusion criteria were the same as for PFS, except studies did not have to select for DNA repair biomarkers. Additional exclusion criteria for adverse effects were: 1) studies did not report adverse effects, and 2) studies did not report adverse effects as total per treatment arm and was therefore unable to be compared with other studies.

228

229 **Outcomes**

The primary outcome was PFS defined as the time from randomisation to disease progression or death. Secondary endpoint was to determine common adverse effects and serious adverse effects (grade 3 and 4) of PARP inhibitors in combination with chemotherapy or chemotherapy alone.

234

235 Data extraction

236 Based on inclusion and exclusion criteria, two reviewers independently identified studies and 237 the following data was recorded: first author information, publication year, disease setting, 238 study design, number of patients, DNA repair status of patients, type of intervention/control, 239 therapeutic doses of treatment and control arms, and outcomes of interest including PFS, hazard ratios (HRs) and 95% confidence intervals (CIs), and the number of each of the selected adverse 240 241 effects. In papers with multiple measures of DNA repair deficiency, we extracted data from 242 subgroups that provided the greatest significant difference [15, 45, 46]. In the case where 243 studies only provided Kaplan-Meier curves [47, 48], the software DigitizeIt was used to digitize 244 the graph and extract the individual event and censoring times. The coxph function in R version 245 4.1.2 [49, 50] was used to calculate the HRs and their CIs from the reconstructed datasets. For 246 the analyses of adverse effects, we recorded the number of patients with selected toxicities 247 treated with PARP inhibitor and chemotherapy and total number of patients treated with PARP

inhibitor and chemotherapy. We also extracted the number of patients with selected toxicities
treated with chemotherapy alone and the total number of patients treated with chemotherapy
alone.

251

252 **Risk-of-bias assessment**

Two investigators independently assessed the quality of the studies included using version 2 of the Cochrane risk of bias tool for randomised trials (RoB 2) [51]. The risk of bias included bias arising due to the randomisation process, bias due to deviations from intended interventions, bias due to missing outcome data, bias in measurement of outcome and bias in selection of the reported result. Each category was judged as high, low or some concerns for risk of bias. Disagreements were resolved through discussion and consensus among the two reviewers.

259

260 Statistical analysis

HR for PFS and 95% CI were extracted from each study or calculated based on survival curves of included papers. Pooled HRs were calculated by the generic inverse-variance method with a fixed-effects model, except as adjusted below following assessment of heterogeneity. Studies were weighted based on variance. For the analysis of risk of an adverse effect, patients with adverse effects assigned to the PARP inhibitor and chemotherapy arm were compared with those assigned to the chemotherapy alone control arm in the same trial for the calculation of risk difference.

268

Statistical heterogeneity was assessed using a Chi-squared (χ^2) test and inconsistency index (I²) test. A fixed effects model was used when I² value was less than 50%. Above 50%, a random effects model was used.

272

- 273 A forest plot was generated to visualise each study and pooled analysis. The weight of each
- study was represented as a square. CIs of each study were indicated as a line across the square.
- 275 The pooled HR or risk difference was represented as a diamond. A p-value of < 0.05 was
- considered significant.

277 **RESULTS**

278 Study selection and characteristics for analysis of PFS

279



Figure 3. PRISMA flow diagram to identify included studies. PFS: progression-free
survival.

For examining the endpoint of PFS, 9 studies were included following the literature search. The PRISMA flow diagram summarises the process of identifying studies (**Figure 3**). The flow chart presents number of studies identified, screened, included, and excluded, and the reasons for exclusion. Title and abstract screening identified 39 possible studies. Of these, 21 studies were excluded because of the following reasons: did not investigate PARP inhibitors combined with chemotherapies (immunotherapies, angiogenesis therapies), were not phase II/III

289 randomised controlled trials (phase I/II safety trials), or only investigated DNA repair deficient 290 (BRCA-mutated) cohorts. After full-text evaluation, 9 studies were excluded because of the 291 following reasons: no data on DNA repair status of patients, unable to extract HR from data 292 provided, data on PFS not available, or reporting of different endpoints of the same clinical 293 trial across multiple publications (trials excluded [20, 52]) The risk-of-bias assessment of the 294 included studies is presented in Supplementary Figure 1. Two studies raised concerns about 295 the randomisation process and outcome measurements due to lack of information about the 296 study, but no studies were excluded.

297

The total sample size of the included studies for PFS analysis was 2,084 patients. All included studies reported the effect of PARP inhibitors in combination with chemotherapy versus chemotherapy alone in terms of PFS [15, 45-48, 53-56]. Three studies recruited patients with ovarian cancer, two with breast cancer, two with small cell lung cancer, one with gastric cancer and one with melanoma. The main characteristics of included studies are listed in **Table 2**.

303

Results were stratified for DNA repair status (deficient or competent). A patient was considered DNA repair deficient if they had an alteration (mutation, loss, or gain) of a gene involved in DNA repair that has been demonstrated to render increased sensitivity to PARP inhibitors. These included *BRCA1*, *BRCA2*, ATM, SFLN11 and ERCC1. Alternatively, a patient was deemed DNA repair deficient if they were greater than cut-off of 30% on the BRCAPRO test, or greater than 42 on 'HRD-score" (Table 1).

310

A patient was deemed DNA repair competent if their cancer lacked alterations in the DNA repair marker in the study. Some studies used multiple markers of DNA repair status, and the marker used with respect to each study is specified in the following analyses. After these

- 314 considerations, 717 patients were DNA repair deficient, and 1,367 patients were DNA repair
- 315 competent for the purpose of the meta-analysis.

Biomarker	Method of	Cut-off / Discriminating factor
	measurement	
BRCA	DNA	Documented deleterious $BRCA1/2$ mutation, Myriad BRACAnalysis CDx or BRCAPRO score of > 30% (this is an algorithm that predicts whether a person has inherited a $BRCA$ gene mutation)
HRD-score	DNA	HRD-score of > 42
SLFN11	IHC	H-score ≥1
ATM	IHC	A clinical status of ATM-positive was assigned to cases with 25% or more gastric cancer cells exhibiting nuclear staining (of weak, moderate, or strong staining intensity) and an ATM-negative status to cases with less than 25% nuclear staining.
ERCC1	IHC	Expression of ERCC1 was defined by immunohistochemistry scores as high $(2+, 3+)$ or low $(0, 1+)$

316 **Table 1. Markers of DNA repair deficiency.**

317	HRD-score: Homologous recombination deficiency sco	ore.
-----	--	------

318 Study selection and characteristics for analysis of adverse effects



Figure 4. PRISMA flow diagram for identifying studies involving adverse effects of
combination PARP inhibitor and chemotherapy.

321 For examining the endpoint of adverse effects, eight studies were included following the 322 literature search. The PRISMA flow diagram summarises the process of identifying studies 323 (Figure 4). To identify these studies, we screened the literature using the same key words as 324 for the primary meta-analysis but adjusted our inclusion/exclusion criteria to remove the 325 requirement for DNA repair biomarkers. Title and abstract screening identified 39 possible 326 studies. Of these, 21 studies were excluded because of the following reasons: did not 327 investigate PARP inhibitors combined with chemotherapies (immunotherapies, angiogenesis 328 therapies) or were not phase II/III randomised controlled trials (phase I/II safety trials). After 329 full-text evaluation, seven studies were excluded because they did not provide data for adverse 330 effects or were not comparable because they did not report patient totals per treatment arm. 331 Note that four studies from our previous analyses on PFS also reported adverse effects that 332 were able to be combined and compared, as in Table 2. Sharma et al [46] did not report adverse 333 effects and the four other studies did not provide data for "any" adverse effects or "Any" grade 334 3/4 adverse effects. Since we were interested in tolerability of combination therapy regardless 335 of underlying DNA repair function, we included an additional seven studies that reported 336 adverse effects associated with combination PARP inhibition and chemotherapy that did not 337 qualify for the meta-analysis on PFS. In total, we found eight studies that reported adverse effects on combination PARP inhibitor and chemotherapy compared to chemotherapy alone 338 339 (Table 2). The risk-of-bias assessment of the included studies is presented in Supplementary 340 Figure 2. Several studies were not double-blinded or were open label, leading to some 341 concerns of bias, but were not excluded from the analysis.

342

The total sample size of the included studies for analysis of adverse effects was 4,498 patients. All included studies reported the adverse effects of PARP inhibitors in combination with chemotherapy vs chemotherapy alone, [15, 16, 45, 53, 56-62]. For analysis of adverse effects,

- a total of 2,347 patients were analysed in the combination PARP inhibitor and chemotherapy
- arm and a total of 2,151 patients in the chemotherapy alone arm. The main characteristics of
- 348 included studies are listed in **Table 2**.

349 Table 2. Characteristics of included studies.

Study	Disease setting	Experimental arm	Control arm	DNA repair biomarker	DNA repair deficient	DNA repair competent	PARP inhibitor dose	Chemotherapy dose	Analyses
Coleman 2019 [15]	Metastatic high-grade serous ovarian cancer	Veliparib + Carboplatin/ Paclitaxel	Carboplatin/ Paclitaxel	BRCA1/2 & HRD-score	200	249	Veliparib at a dose of 150 mg twice daily	Carboplatin given at AUC of 6 mg/ml/minute and paclitaxel 175 mg/m ²	PFS and AE
Kummar 2015 [47]	Primary high- grade serous ovarian cancer	Veliparib + Cyclophosphamide	Cyclophosphamide	BRCAPRO score	28	25	Veliparib 60mg once daily	Cyclophosphamide 50mg once daily	PFS
Oza 2015 [56]	Primary high- grade serous ovarian cancer	Olaparib + Carboplatin/ Paclitaxel	Carboplatin/ Paclitaxel	BRCA1/2	41	66	Olaparib 200mg twice daily	Paclitaxel 175 mg/m ²	PFS and AE
Geyer 2022 [54]	Primary triple- negative breast cancer	Veliparib + Carboplatin/ Paclitaxel	Carboplatin/ Paclitaxel	BRCA1/2	70	406	Veliparib 50mg twice daily	Carboplatin at AUC of 6 mg/ml/min and paclitaxel 80 mg/m ²	PFS
Sharma 2020 [46]	Metastatic triple-negative breast cancer	Veliparib + Cisplatin	Cisplatin	BRCA1/2 & HRD-score	101	110	Veliparib 300mg twice daily	Cisplatin 75mg/m ²	PFS
Dieras 2020 [57]	Metastatic breast cancer	Veliparib + Carboplatin/Paclitaxel	Carboplatin/Paclitaxel	BRCA1/2	509	N/A	Veliparib 120mg twice daily	Carboplatin given at AUC of 6mg/mL/min and paclitaxel 80mg/m ²	AE
Han 2020 [58]	Metastatic breast cancer	Veliparib + Carboplatin/Paclitaxel	Carboplatin/Paclitaxel	BRCA1/2	294	N/A	Veliparib 40mg twice daily	Carboplatin given at AUC 6mg/mL/min and paclitaxel 175mg/m ²	AE
Pietanza 2018 [48]	Metastatic small cell lung cancer	Veliparib + Temozolomide	Temozolomide	SLFN11	25	23	Veliparib 40mg twice daily	Temozolomide 200 mg/m ²	PFS
Byers 2021 [53]	Metastatic small cell lung cancer	Veliparib + Carboplatin/ Etoposide	Carboplatin/ Etoposide	SLFN11	47	43	Veliparib 240 mg twice daily	Carboplatin given at AUC of 5 mg/mL/min and etoposide 100 mg/m ²	PFS and AE
Govindan 2022 [60]	Metastatic non- small cell lung cancer	Veliparib + Carboplatin/Paclitaxel	Carboplatin/Paclitaxel	N/A	595	N/A	Veliparib 120mg twice daily	Carboplatin given at AUC 6mg/mL/min and paclitaxel 200mg/m ²	AE

Ramalingam 2021 [16]	Metastatic squamous non- small cell lung cancer	Veliparib + Carboplatin/Paclitaxel	Carboplatin/Paclitaxel	N/A	970	N/A	Veliparib 120mg twice daily	Carboplatin given at AUC 6mg/mL/min and paclitaxel 200mg/m ²	AE
Liu 2018 [45], Bang 2017 [20]	Metastatic gastric cancer	Olaparib + Paclitaxel	Paclitaxel	ATM	76	324	Olaparib 100 mg twice daily	Paclitaxel 80 mg/m ²	PFS and AE
Middleton 2015 [55]	Metastatic melanoma	Veliparib + Temozolomide	Temozolomide	ERCC1	129	121	Veliparib 40 mg twice daily	Temozolomide 150 mg/m ²	PFS

350 HRD-score: homologous recombination deficiency score; PFS: progression-free survival; AE: adverse effect. Studies are organised based on

351 cancer subtype.

352 DNA REPAIR DEFICIENT PATIENTS SHOW BENEFIT IN PFS, BUT DNA

353 **REPAIR COMPETENT PATIENTS DO NOT**





B) DNA repair competent patients, n=1,367



354

Figure 5. Comparative effects of combination PARP inhibitor and chemotherapy vs chemotherapy alone in A) DNA repair deficient patients (n=717) and in B) DNA repair competent patients (n=1,367). Results were presented as individual and pooled hazard ratio (HR) with 95% confidence interval (CI). SE: standard error; IV: inverse-variance.

To evaluate the effect of PARP inhibitor in combination with chemotherapy in DNA repair deficient patients, we conducted a pooled analysis to compare the PFS between PARP inhibitor in combination with chemotherapy and the chemotherapy alone group. In total, all 9 studies were pooled for this analysis. For our analysis, a patient was considered DNA repair deficient

364 if they had an alteration of a gene involved in DNA repair that has been demonstrated to render 365 increased sensitivity to PARP inhibitors (Table 1). For Byers (2021) and Pietanza (2018), we 366 considered SLFN11-positive patients as DNA repair deficient, and SLFN11-negative patients 367 as DNA repair competent [52]. For Geyer (2022), Oza (2015) and Kummar (2015), patients 368 with a BRCA1/2 mutation were considered DNA repair deficient and those with no mutation 369 in BRCA1/2 were considered DNA repair competent [53,55]. Additionally, in Kummar (2015), 370 patients were considered DNA repair deficient if they had a BRCAPRO score of >30%. For 371 Liu (2018), ATM-negative patients were considered DNA repair deficient and ATM-positive 372 patients were considered DNA repair competent [44]. For Middleton (2015), low ERCC1 373 expression was considered DNA repair deficient and high ERCC1 expression was considered 374 DNA repair competent [54].

375 In the Coleman (2019) and Sharma (2020) studies, there were multiple biomarkers of impaired 376 DNA repair. For analysis of Coleman (2019), we used "BRCA-mutated" (patients who had 377 germline or tissue-based mutations as determined by the Myriad BRACAnalysis CDx and 378 myChoice homologous recombination deficiency CDx assay, respectively. 379 in BRCA1 or BRCA2) cohort as our "DNA repair deficient" and the "non-homologous 380 recombination deficiency" (no genetic evidence of homologous recombination deficiency) 381 cohort as "DNA repair competent" [15]. For Sharma (2020), patients were classified into 382 "BRCA-like" (included myChoice homologous recombination deficiency score, 383 somatic BRCA1/2 mutations, BRCA1 methylation and non-*BRCA1/2* homologous 384 recombination germline mutations) and "non-BRCA-like". For our analysis, we defined 385 "BRCA-like" as DNA repair deficient, and "non-BRCA-like" as DNA repair competent.

386

387 717 DNA repair deficient patients received either PARP inhibitor in combination with388 chemotherapy or chemotherapy alone. Pooled analysis on the DNA repair deficient population

389	showed that PARP inhibitor in combination with chemotherapy, compared to chemotherapy
390	alone, was significantly associated with improved PFS (HR:0.52, 95% CI: 0.43-0.63, p <
391	0.00001) (Figure 5A).
392	
393	1,367 DNA repair competent patients were pooled for analysis. No significant difference in
394	PFS was observed in DNA repair competent patients with PARP inhibitor in combination with
395	chemotherapy compared to chemotherapy alone (HR: 0.94, 95% CI: 0.81-1.08, p = 0.38)

396 (Figure 5B).

397

398 There was some heterogeneity in these studies including DNA repair deficient patients 399 (Chi²=7.16), although this was non-significant, and the inconsistency score (I^2) was 0%.

400

401 In the subsequent sections we performed subgroup analyses to determine if there were any 402 factors, including cancer subtype, DNA repair biomarker, or therapy subtype, which could be 403 significantly contributing to the heterogeneity of response.

404

405 1. DNA REPAIR STATUS DICTATES BENEFIT, REGARDLESS OF CANCER 406 SUBGROUP

We next analysed response within cancer subtypes to determine if benefit from combination therapy could be mainly attributed to certain cancer subtypes. We pooled studies that had two or more trials investigating the same cancer type. The combination therapy significantly improved PFS in DNA repair deficient patients in ovarian cancer (HR: 0.44, 95% CI: 0.31-0.64, p < 0.00001), breast cancer (HR: 0.57, 95% CI: 0.38-0.86, p = 0.007) and small cell lung cancer (HR: 0.47, 95% CI: 0.26-0.85, p = 0.01) (**Figure 6A(i), B(i), C(i)**). In contrast, DNA

413 repair competent patients had no associated improvement in PFS from the combination therapy

414 in any of the cancer subtypes (Figure 6A(ii), B(ii), C(ii)).

A) Ovarian cancer

(i) DNA repair deficient patients, n=269



Figure 6. Comparative effects of combination PARP inhibitor and chemotherapy vs
chemotherapy alone separated by cancer subgroup. A) Ovarian cancers with (i) DNA

417	repair deficient patients (n=269) and (ii) DNA repair competent patients (n=280). B)
418	Breast cancers with (i) DNA repair deficient patients (n=171) (ii) DNA repair competent
419	patients (n=516). C) Small cell lung cancers with (i) DNA repair deficient patients (n=72)
420	and (ii) DNA repair competent patients (n=66). Results were presented as individual and
421	pooled hazard ratio (HR) with 95% confidence interval (CI). SE: standard error; IV:
422	inverse-variance.
423	

424

425

2. DNA REPAIR FUNCTION STATUS DICTATES BENEFIT, REGARDLESS OF BIOMARKER SUBGROUP



				Hazard Ratio	Hazard Ratio	
Study or Subgroup	log[Hazard Ratio]	SE	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% Cl	
Coleman 2019	-0.2107	0.1531	43.1%	0.81 [0.60, 1.09]		
Geyer 2022	0.1662	0.2454	16.8%	1.18 [0.73, 1.91]		
Kummar 2015	0.1906	0.4309	5.4%	1.21 [0.52, 2.82]		
Oza 2015	-0.2614	0.3216	9.8%	0.77 [0.41, 1.45]		
Sharma 2020	-0.1165	0.2012	24.9%	0.89 [0.60, 1.32]		
Total (95% CI)			100.0%	0.90 [0.74, 1.09]	, , + ,	
Heterogeneity: $Chi^2 = 2.41$, $df = 4$ (P = 0.66); $l^2 = 0$ Test for overall effect: Z = 1.07 (P = 0.29)					0.05 0.2 1 5 Favours PARPi+Chemo Favours Chemo ale	20 one

Figure 7. Comparative effects of combination PARP inhibitor and chemotherapy vs chemotherapy alone separated by *BRCA* status. A) DNA repair deficient, *BRCA*-like patients (n=440) B) DNA repair competent, non-*BRCA*-like patients (n=856). Results were presented as individual and pooled hazard ratio (HR) with 95% confidence interval (CI). SE: standard error; IV: inverse-variance.

We next looked at pooled biomarkers to explore whether benefit from PARP inhibitor incombination with chemotherapy was only associated with certain biomarkers of DNA repair

433 function. First, we examined studies that incorporated patients with "BRCA-like" biology. 434 These studies included patients that were categorised based on BRCA1/2 mutation or a 435 surrogate marker to categorise cancers as DNA repair deficient due to a 'BRCA-like' event. 436 Two papers in this analysis incorporated surrogate *BRCA*-like markers [15, 46]. Sharma (2020) 437 defined the 'BRCA-like' group with 4 markers: homologous recombination deficiency genomic 438 instability score of > 42, somatic BRCA1/2 mutation, BRCA1 promoter methylation, and 439 germline DNA repair gene mutations other than *BRCA1/2*. Positivity on any 1 of the 4 markers 440 placed a patient in the BRCA-like group. 'Non-BRCA-like' patients included patients that did 441 not have any of the 4 markers above. In Coleman (2019), multiple measures of BRCA1/2 status 442 were compared including germline BRCA1/2 mutation (gBRCAmut), and 'BRCA-like' patients 443 include those that have somatic and germline BRCA1/2 gene mutations and/or a 'BRCA-like' 444 phenotype based on DNA repair deficiency assays. We extracted data from 'gBRCAmut' for 445 the purpose of this subgroup analysis, as Coleman et al concluded that it was a better 446 discriminator for improvement in survival based on their analyses.

447

BRCA-like patients showed significant improvement in PFS with the combination therapy (HR: 0.50, 95% CI: 0.38-0.65, p < 0.00001) (**Figure 7A**). There was no significant difference in the PFS of non-BRCA-like patients with the addition of PARP inhibitor (HR: 0.90, 95% CI: 0.74-1.09, p = 0.29) (**Figure 7B**). There was some heterogeneity observed in the analysis of the *BRCA*-like, DNA repair deficient patients (Chi² = 5.43, I² = 26%) likely due to the variability of definition of "*BRCA*-like" in these studies, although this was not enough to perform a random effects model.

455

Both studies of small cell lung cancer were performed with the biomarker SFLN11. Highexpression of SFLN11 was associated with increased PFS in patients treated with combination

therapy (Figure 6C(i), (ii)). Patients with absent SFLN11 did not show any improvement in
PFS with combination therapy.

460

461 Overall, the *BRCA*-like and SFLN11 biomarkers were both able to discriminate patient 462 populations with an improved PFS when treated with combination therapy.

463

464 3. INVESTIGATION OF THE BENEFIT ASSOCIATED WITH SPECIFIC PARP 465 INHIBITORS OR CHEMOTHERAPIES USED IN COMBINATIONS

466 We next considered whether the type of PARP inhibitor or the type of chemotherapy could 467 influence the benefit seen in PFS following combination therapy. Two PARP inhibitors were 468 used in these studies, veliparib (7 studies) [15, 46-48, 53-55] and olaparib (2 studies) [45, 56]. 469 Notably, there was variability in dosing, scheduling, and length of treatments. Veliparib and 470 olaparib were given twice daily, except for one study where veliparib was given once daily 471 [47]. Doses of veliparib ranged from 20mg to 400mg and olaparib ranged from 100mg to 472 400mg. The length of treatment cycles varied between studies from 14-days to 28-day cycles. 473 The number of cycles patients received also varied from patients receiving 1 cycle of treatment, 474 to patients receiving 30 cycles of treatment.

475

476 A significant benefit to PFS was seen for DNA repair deficient patients treated with 477 combination therapy regardless of the type of PARP inhibitor, whereas no benefit was seen in 478 DNA repair competent patients (**Figure 8**). Even though the conditions of treatment were 479 highly variable, there was little heterogeneity in studies that included veliparib treatment (DNA 480 repair deficient: $Chi^2=3.42$, DNA repair competent: $Chi^2=3.99$), and the inconsistency score 481 (I²) was 0%. Only two studies examined olaparib treatment which probably led to the 482 considerable heterogeneity (I² =72%) between those studies as they were conducted on

483 different cancer types with different treatment regimes. Consequently, we applied a random

484 effects model to this analysis, and to the other analyses of olaparib for consistency.



Figure 8. Comparative effects of combination PARP inhibitor and chemotherapy vs chemotherapy alone separated by type of PARP inhibitor. A) Veliparib in DNA repair deficient patients (n=600) B) Veliparib in DNA repair competent patients (n=977) C) Olaparib in DNA repair deficient patients (n=117) D) Olaparib in DNA repair competent patients (n=390). A) and B) were analysed using fixed effects model. C) and D) were analysed using random effects model. Results were presented as individual and pooled

491 hazard ratio (HR) with 95% confidence interval (CI). SE: standard error; IV: inverse-

492 variance.

A) Platinum-based chemotherapy

(i) [(i) DNA repair deficient patients, n=459										
Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95% CI	Hazaro IV, Fixed	l Ratio , 95% Cl					
Byers 2021	-0.5108	0.3889	12.4%	0.60 [0.28, 1.29]		_					
Coleman 2019	-0.8293	0.2264	36.6%	0.44 [0.28, 0.68]							
Geyer 2022	-0.1705	0.5273	6.7%	0.84 [0.30, 2.37]							
Oza 2015	-1.5606	0.4924	7.7%	0.21 [0.08, 0.55]							
Sharma 2020	-0.6349	0.2265	36.5%	0.53 [0.34, 0.83]							
Total (95% CI)			100.0%	0.48 [0.37, 0.63]	•						
Heterogeneity: Chi ² =	4.66, $df = 4 (P = 0.1)$	32); I ² =	14%								
Test for overall effect:	Z = 5.34 (P < 0.000	001)			0.05 0.2 J Favours PARPi+Platinum	Favours Platinum alone					
(ii)	DNA repair co	mpete	ent pat	ients, n=874							

			Hazard Katio	Hazard Ratio
Study or Subgroup	log[Hazard Ratio] SI	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Byers 2021	-0.0513 0.2025	20.7%	0.95 [0.64, 1.41]	
Coleman 2019	-0.2107 0.1531	. 36.1%	0.81 [0.60, 1.09]	
Geyer 2022	0.1662 0.2454	14.1%	1.18 [0.73, 1.91]	
Oza 2015	-0.2614 0.3216	8.2%	0.77 [0.41, 1.45]	
Sharma 2020	-0.1165 0.2012	20.9%	0.89 [0.60, 1.32]	
Total (95% CI)		100.0%	0.90 [0.75, 1.07]	•
Heterogeneity: $Chi^2 = 2.01$, $df = 4$ (P = 0.73); $I^2 = 09$				0.05 0.2 1 5 20
Test for overall effect:	Z = 1.19 (P = 0.24)			Favours PARPi+Platinum Favours Platinum alone

B) Non-platinum-based chemotherapy

(i) DNA repair deficient patients, n=258



493

Figure 9. Comparative effects of combination PARP inhibitor and chemotherapy vs chemotherapy alone separated by type of chemotherapy. A) Platinum-based chemotherapy in (i) DNA repair deficient patients (n=459) and (ii) DNA repair competent patients (n=874). B) Non-platinum-based chemotherapy in (i) DNA repair deficient patients (n=258) and (ii) DNA repair competent patients (n=493). Results were presented

499 as individual and pooled hazard ratio (HR) with 95% confidence interval (CI). SE: 500 standard error; IV: inverse-variance.

501

The chemotherapy treatment across the 9 trials was highly varied, and included carboplatin, etoposide, paclitaxel, cyclophosphamide, and etoposide. Each trial also used different doses and schedules of chemotherapy treatment. However, the trials could be broadly separated into trials that included platinum-based therapies (carboplatin and cisplatin) and non-platinum therapies (cyclophosphamide, temozolomide and paclitaxel). As DNA repair deficient cancers are frequently more sensitive to platinum-based drugs [63], we considered whether the benefit of combination therapy is altered with this treatment.

509

A significant benefit to PFS was seen for DNA repair deficient patients treated with either platinum-based or other combination therapies. There was no improvement to PFS in DNA repair competent patients regardless of whether the chemotherapy included platinum-based drugs (**Figure 9**).

ADVERSE EFFECTS: NO OVERALL INCREASE IN THE FREQUENCY OF ADVERSE EFFECTS, BUT SIGNIFICANTLY HIGHER GRADE 3/4 EFFECTS

516 **IN COMBINATION TREATED PATIENTS**

- 517 Next, we assessed the secondary endpoint of whether the combination of PARP inhibitors
- and chemotherapy is well tolerated compared to chemotherapy alone. We found eight
- 519 studies that reported adverse effects on combination PARP inhibitor and chemotherapy
- 520 compared to chemotherapy alone. In total, we assessed 3.789 patients with reported adverse
- 521 effects. 1,987 patients were treated with combination PARP inhibitor and chemotherapy
- and 1,802 patients were treated with chemotherapy alone (**Table 3**).

Table 3. Characteristics of studies included in adverse effects analysis. N/A: not available.

Study	All adverse effects (PARP inhibitor + chemotherapy vs chemotherapy alone)	Serious Grade 3/4 adverse effects (PARP inhibitor + chemotherapy vs chemotherapy alone)	Adverse effects with >10% greater incidence in combination therapy
Bang 2017 [20]	99.2% (260/262) vs 98% (254/259)	77.9% (204/262) vs 61.8% (160/259)	Any grade: anaemia, neutrophil count decreased Grade 3/4: N/A
Byers 2021 [53]	96.7% (58/60) vs 96.7% (58/60)	81.7% (49/60) vs 68.3% (41/60)	Any grade: pneumonia Grade 3/4: neutropenia, anaemia, thrombocytopenia
Coleman 2019 [15]	100% (377/377) vs 100% (371/371)	88% (332/377) vs 76.8% (285/371)	Any grade: nausea, anaemia thrombocytopenia, vomiting Grade 3/4: anaemia, thrombocytopenia
Dieras 2020 [57]	99.4% (334/336) vs 100% (171/171)	96.4% (324/336) vs 95.3% (163/171)	Any grade: N/A Grade 3/4: infections after neutropenia, hematopoietic thrombocytopenia
Govindan 2022 [60]	97.6% (286/293) vs 96.2% (277/288)	67.6% (198/293) vs 56.3% (162/288)	Any grade: alopecia, peripheral sensory neuropathy Grade 3/4: neutropenia
Han 2018 [58]	100% (93/93) vs 97.9% (94/96)	78.5% (73/93) vs 83.3% (80/96)	Any grade: bone pain, diarrhoea, nausea, upper respiratory tract infection Grade 3/4: N/A
Oza 2015 [56]	100% (81/81) vs 97.3% (73/75)	65.4% (53/81) vs 57.3% (43/75)	Any grade: alopecia, nausea, diarrhoea, headache, peripheral neuropathy, dyspepsia, neutropenia Grade 3/4: N/A
Ramalingam 2021 [16]	95.9% (465/485) vs 95.9% (462/482)	60.2% (292/485) vs 58.3% (281/482)	Any grade: N/A Grade 3/4: N/A

A) All adverse effects, n=3,789

PARPi + Chemotherapy Chemotherapy			Risk Difference	Risk Difference			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
Bang 2017	260	262	254	259	12.2%	0.01 [-0.01, 0.03]	-
Byers 2021	58	60	58	60	1.5%	0.00 [-0.06, 0.06]	
Coleman 2019	377	377	371	371	40.1%	0.00 [-0.01, 0.01]	•
Dieras 2020	334	336	171	171	22.8%	-0.01 [-0.02, 0.01]	+
Govindan 2022	286	293	277	288	6.9%	0.01 [-0.01, 0.04]	+-
Han 2018	93	93	94	96	4.8%	0.02 [-0.01, 0.06]	+
Oza 2015	81	81	73	75	3.2%	0.03 [-0.02, 0.07]	+
Ramalingam 2021	465	485	462	482	8.4%	0.00 [-0.02, 0.03]	+
Total (95% CI)		1987		1802	100.0%	0.00 [-0.01, 0.01]	•
Total events	1954		1760				
Heterogeneity: Tau ² = 0.00; Chi ² = 10.00, df = 7 (P = 0.19)			$l^2 = 305$	%	н. На		
Test for overall effect	Z = 0.72 (P = 0.47)	7)				-0	Favours PARPi+Chemo Favours Chemo alone

B) Severe grade 3/4 adverse effects, n=3,789

	PARPi + Chemot	herapy	Chemothe	erapy		Risk Difference	Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M–H, Random, 95% Cl
Bang 2017	204	262	160	259	13.5%	0.16 [0.08, 0.24]	
Byers 2021	49	60	41	60	7.2%	0.13 [-0.02, 0.29]	
Coleman 2019	332	377	285	371	15.9%	0.11 [0.06, 0.17]	
Dieras 2020	324	336	163	171	17.5%	0.01 [-0.03, 0.05]	
Govindan 2022	198	293	162	288	13.4%	0.11 [0.03, 0.19]	
Han 2018	73	93	80	96	10.2%	-0.05 [-0.16, 0.06]	
Oza 2015	53	81	43	75	7.3%	0.08 [-0.07, 0.23]	
Ramalingam 2021	292	485	281	482	15.1%	0.02 [-0.04, 0.08]	
Total (95% CI)		1987		1802	100.0%	0.07 [0.02, 0.12]	◆
Total events	1525		1215				
Heterogeneity: Tau ² =	= 0.00; Chi ² = 26.8	4, df = 7	(P = 0.000)	4); I ² = 1	74%		
Test for overall effect	Z = 2.63 (P = 0.00	09)					Favours PARPi+Chemo Favours Chemo alone

C) Neutropenia grade 3/4 adverse effects, n=3,789

	PARPi + Chemoth	ierapy	Chemothe	erapy		Risk Difference	Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
Bang 2017	78	262	59	259	14.4%	0.07 [-0.01, 0.15]	
Byers 2021	34	60	24	60	3.2%	0.17 [-0.01, 0.34]	
Coleman 2019	218	377	183	371	15.7%	0.08 [0.01, 0.16]	
Dieras 2020	278	336	143	171	16.6%	-0.01 [-0.08, 0.06]	
Govindan 2022	85	293	53	288	16.6%	0.11 [0.04, 0.17]	
Han 2018	52	93	53	96	4.9%	0.01 [-0.13, 0.15]	
Oza 2015	35	81	26	75	4.2%	0.09 [-0.07, 0.24]	
Ramalingam 2021	116	485	95	482	24.3%	0.04 [-0.01, 0.09]	+-
Total (95% CI)		1987		1802	100.0%	0.06 [0.03, 0.09]	◆
Total events	896		636				
Heterogeneity: Tau ² =	= 0.00; Chi ² = 8.73,	df = 7 (P = 0.27); l ⁱ	$^{2} = 20\%$			
Test for overall effect:	Z = 3.57 (P = 0.00)	04)					Favours PARPi+Chemo Favours Chemo alone

Figure 10. Adverse effects of combination of PARP inhibitor and chemotherapy vs
chemotherapy alone. A) All adverse effects B) Severe grade 3/4 adverse effects
C) Neutropenia grade 3/4 adverse effects (n=3,789). Results were presented as individual
and pooled risk difference with 95% confidence interval (CI). M-H: Mantel-Haenszel.

529

530 Pooled data were stratified for all adverse effects and data was analysed using risk difference.

531 We note that there are inconsistencies in the reporting of adverse effects (reported variously as

532 occurring in >5% vs >10% vs >20% of patients), and different adverse effects were reported

533 in each study. This is likely to have contributed to heterogeneity within the analyses. Our initial

analysis demonstrated high heterogeneity in the analysis of grade 3/4 adverse effects (I² = 74%). Consequently, we applied a random effects model to this analysis, and to the other analyses of adverse effects for consistency.

537

538 There was no significant difference in the incidence of all adverse effects between patients 539 treated with combination therapy or chemotherapy alone (RD: 0.00, 95% CI: -0.01-0.01, p = 0.47) (Figure 10A). However, when looking at more severe side effects, the combination 540 541 therapy was associated with a significant increase in the incidence of grade 3/4 adverse effects 542 (RD: 0.07, 95% CI: 0.02-0.12, p = 0.009) (Figure 10B). The high heterogeneity observed with the assessment of grade 3/4 effects led us to perform a more refined analysis on haematological 543 544 effects, as these were very common and reported with greater consistency among the studies. 545 We chose to investigate neutropenia as the most reported haematological effect. We found that 546 neutropenia had increased incidence with the combination therapy (RD: 0.06, 95% CI: 0.03-547 0.09, p = 0.0004) (Figure 10C). The analysis of neutropenia alone did not exhibit high 548 heterogeneity.

549

550 **DISCUSSION**

Several PARP inhibitors are approved by Food and Drug Administration (FDA) and European 551 552 Medicines Agency (EMA) as maintenance therapies following first-line treatments for DNA 553 repair deficient ovarian, breast, pancreatic and prostate cancers. PARP inhibitors are yet to be 554 approved for use as part of short-term therapeutic regimens with curative intent in any 555 malignancy. However, this is an intense area of clinical investigation with a multitude of 556 clinical trials assessing the potential of combining PARP inhibitors with immunotherapies, 557 radiation therapy, chemotherapies, and other therapies to improve rates of success of those 558 therapeutic regimes.

560 Our results, combining nine studies and 2,084 patients across several cancer subtypes, 561 demonstrates that patients with an identifiable DNA repair deficiency may gain an 562 improvement in PFS if PARP inhibitors are combined with chemotherapy as a line of therapy. 563 In contrast, DNA repair competent patients did not show any additional benefit (Figure 5). 564 Furthermore, we found that benefit for DNA repair deficient patients was associated with 565 combination therapy in all cancer subtypes investigated including ovarian, breast and small cell 566 lung cancers (Figure 6). We considered whether certain biomarkers (BRCA-like, SLFN11) 567 would have differences in their associated benefit, but found similar benefit was seen with the 568 combination therapy in DNA repair deficient but not DNA repair competent patients regardless 569 of the biomarker (Figure 7). We observed that the benefit for DNA repair deficient patients 570 was not influenced by either the type of PARP inhibitor (veliparib, olaparib) or chemotherapy 571 (platinum-based, non-platinum-based) (Figure 8&9).

572

573 All subgroup analyses supported the same conclusion that improved PFS from combination 574 therapy was only associated with DNA repair deficiency status. However, there were several 575 limitations to our study. First, each study involved different chemotherapies, PARP inhibitor 576 and dosing regimens. This likely contributed to the heterogeneity observed across some of the subgroup analyses and analysis of adverse effects. To address issues of heterogeneity, we 577 578 applied a random effects model to analyses where heterogeneity was greater than 50%, but the 579 addition of more studies would be informative. A second limitation of this meta-analysis is that 580 we were unable to assess the impact of treatment and DNA repair deficiency status on overall 581 survival, as those data are not yet available due to the immaturity of trials in this area.

582

583 While this meta-analysis did not show any benefit in DNA repair competent cancers, it should 584 also be considered whether the most optimal PARP inhibitors and chemotherapies were used

585 in the combination therapies in these trials. Of note, both of the PARP inhibitors used in these 586 analysed studies, veliparib and olaparib, have weak PARP trapping ability [64, 65]. Synergy 587 with chemotherapy has been suggested to be dependent upon PARP trapping [27], and the 588 combination of chemotherapy with efficient PARP trappers such as talazoparib [66] may 589 provide greater synergistic effects. A drawback of PARP inhibitors with higher trapping ability, 590 is the potential for greater challenges with toxicity. However, a recent phase I study 591 investigated the safety of combined talazoparib and carboplatin/paclitaxel and found that the 592 combination is feasible with an intermittent, lower dose schedule of talazoparib and appropriate 593 supportive care [67]. Further investigation into the dosing regimen may assist in enhancing 594 anti-tumour efficacy whilst improving tolerability.

595

596 PARP inhibitors are only approved for DNA repair deficient cancers. The exception is 597 niraparib, which is approved as first line maintenance therapy regardless of homologous 598 recombination deficiency status for ovarian cancers that have shown a response to platinum 599 therapies. Response to platinum salts is correlated with the presence of homologous 600 recombination deficiency [68], and has high penetrance in ovarian cancer with up to 69% 601 classified as homologous recombination deficient [69]. Thus, it may be that the high penetrance 602 of homologous recombination deficiency in ovarian cancers leads to a more general 603 susceptibility to PARP inhibitors, alone or in combination with chemotherapies. Interestingly, 604 from our subgroup analysis of ovarian cancers without a homologous recombination 605 deficiency, there was an overall weighted average effect of 1.38 with combination therapy, 606 although this was not significant (p<0.17; HR: 0.83; CI 0.64-1.08). Since this subgroup analysis 607 only includes 340 patients over three studies, the addition of further studies may indicate 608 benefit for combination PARP inhibitors and chemotherapy in ovarian cancer patients that do 609 not have canonical homologous recombination deficiency indicators such as BRCA1/BRCA2

610 mutation. This should be re-examined if more clinical trials are reported on PARP 611 inhibitor/chemotherapy combinations for ovarian cancer.

612

613 A major consideration in this analysis is that the definition of DNA repair deficiency is highly 614 heterogeneous, with individual clinical trials using different methods and cut-offs to assess a 615 patient's DNA repair deficiency status. This raises the question of whether there should be a 616 uniform definition of DNA repair deficiency, or if each cancer subtype will require its own 617 specific biomarkers. SFLN11 is an emerging biomarker of PARP inhibitor sensitivity, but 618 unlike mutations to homologous recombination pathway genes it does not appear to be 619 associated with the presence of genomic scars [22]. Instead SFLN11 is actively recruited to 620 sites of DNA damage to inhibit homologous recombination [70], and its high expression is correlated with PARP inhibitor sensitivity [22]. This seems to be particularly relevant for small 621 622 cell lung cancer [53], but a retrospective analysis of 110 ovarian cancers treated with PARP 623 inhibitor suggests there could be broader application [71]. In that study, BRCA-wildtype 624 ovarian cancer patients with high SFLN11 showed non-significant improvements in olaparib 625 response compared to SFLN11 low patients [71]. Overall, each of these biomarkers should be 626 assessed in each cancer setting for its frequency, overlap with other DNA repair biomarkers, 627 and its potential as an indicator of PARP inhibitor sensitivity.

628

An area that was not explored with this meta-analysis was whether non-DNA repair markers may be predictive of benefit from combination PARP inhibitors and chemotherapy. In the study of Ramalingam *et al* [16] the LP52, a 52 gene panel that was first generated to differentiate squamous non-small cell lung cancer subtypes, was predictive of a better response to veliparib in combination with carboplatin/paclitaxel. A similar, but non-significant, trend was seen in the study of Govindan *et al* on veliparib with carboplatin/paclitaxel versus

physician's choice of standard chemotherapy in advanced non-squamous non-small cell lung
cancer [60]. Thus, alternative markers may provide more guidance for combination therapy,
especially in those cancer types without a high penetrance of DNA repair deficiencies.

638

639 Our secondary analysis of the adverse effects associated with combination treatment versus 640 chemotherapy alone revealed that combination therapy had higher associated toxicities. Grade 641 3/4 adverse effects and neutropenia were significantly higher with chemotherapy and PARP 642 inhibitor combination therapy, although there was no increase in overall effects of all grades. 643 A confounding issue was the significant heterogeneity we observed when considering grade 644 3/4 adverse effects (Figure 10B). This was most likely due to the differences in criteria used 645 for adverse effects in each clinical trial. Re-analysis of the data for neutropenia alone 646 demonstrated an increased risk with combination therapy, and the data showed very little 647 heterogeneity for this sub-analysis. Data from further clinical trials are needed to resolve 648 whether other haematological and non-haematological side-effects are significantly associated 649 with the combination of chemotherapy and PARP inhibitors. Despite these side-effects, it is 650 important to note that the PFS benefit with the combination of PARP inhibitor and 651 chemotherapy was achieved despite dose modifications occurring in most of the studies. Most studies found that the combination therapy had a manageable toxicity profile. 652

653

In conclusion, DNA repair deficiency associates with improved PFS following combination PARP inhibitor and chemotherapy compared to chemotherapy alone, but there is no associated benefit for DNA repair competent patients. Despite the potential to improve outcome for DNA repair deficient patients, the benefit must be weighed against the increase in associated toxicities. Results show that combined PARP inhibitor and chemotherapy are associated with an increase in severe adverse effects, particularly neutropenia, compared to chemotherapy

660 alone. Previous meta-analyses have shown that haematological side-effects are very common 661 with PARP inhibitors [72], and this effect is likely to be compounded with the addition of 662 chemotherapy. Whilst this may prevent the effective use of these combinations, there are 663 existing strategies to manage haematological side-effects, such as dose interruptions, dose 664 reductions and in appropriate patients, treat with granulocyte colony- stimulating factors to 665 help stimulate neutrophil production [73, 74], and these could be applied in the combination setting along with close monitoring of patients. To our knowledge, this is the first synthesised 666 667 analysis of the efficacy of combination PARP inhibitor and chemotherapy across multiple 668 malignancies to demonstrate that this benefit is dependent upon the presence of a DNA repair 669 biomarker.

670 **REFERENCES**

671	1.	Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pineros M, Znaor A, Bray F:
672		Cancer statistics for the year 2020: An overview. International journal of cancer
673		2021.
674	2.	Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, De P,
675		Krie A, Piccioni DE, Miller VA et al: Molecular profiling of cancer patients
676		enables personalized combination therapy: the I-PREDICT study. Nat Med 2019,
677		25 (5):744-750.
678	3.	Pilié PG, Gay CM, Byers LA, O'Connor MJ, Yap TA: PARP Inhibitors: Extending
679		Benefit Beyond BRCA-Mutant Cancers. Clin Cancer Res 2019, 25(13):3759-3771.
680	4.	Yousefzadeh M, Henpita C, Vyas R, Soto-Palma C, Robbins P, Niedernhofer L: DNA
681		damage—how and why we age? <i>Elife</i> 2021, 10:e62852.
682	5.	Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL,
683		Meier W, Shapira-Frommer R, Safra T et al: Olaparib maintenance therapy in
684		patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned
685		retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
686		<i>The Lancet Oncology</i> 2014, 15 (8):852-861.
687	6.	Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W,
688		Tung N, Armstrong A et al: Olaparib for Metastatic Breast Cancer in Patients
689		with a Germline BRCA Mutation. N Engl J Med 2017, 377(6):523-533.
690	7.	Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO,
691		Hochhauser D, Arnold D, Oh DY et al: Maintenance olaparib for germline BRCA-
692		mutated metastatic pancreatic cancer. New Engl J Med 2019, 381(4):317-327.
693	8.	Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N,
694		Weberpals JI, Clamp A, Scambia G et al: Rucaparib maintenance treatment for

695		recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a
696		randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017,
697		390 (10106):1949-1961.
698	9.	Litton JK, Rugo HS, Ettl J, Hurvitz SA, Goncalves A, Lee KH, Fehrenbacher L,
699		Yerushalmi R, Mina LA, Martin M et al: Talazoparib in Patients with Advanced
700		Breast Cancer and a Germline BRCA Mutation. N Engl J Med 2018, 379(8):753-
701		763.
702	10.	Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M,
703		Ledermann JA, Lorusso D, Vergote I et al: Niraparib Maintenance Therapy in
704		Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med 2016,
705		375 (22):2154-2164.
706	11.	Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner
707		Hendrickson AE, Azodi M, DiSilvestro P, Oza AM et al: Niraparib monotherapy
708		for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label,
709		single-arm, phase 2 trial. The Lancet Oncology 2019, 20(5):636-648.
710	12.	Arun BK, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL,
711		Bell-McGuinn KM, Bach BA, Kundu MG et al: Efficacy and safety of first-line
712		veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline
713		BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial.
714		European journal of cancer (Oxford, England : 1990) 2021, 154:35-45.
715	13.	Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P,
716		Waters J, Berek JS, Woie K, Oza AM et al: Niraparib Maintenance Therapy in
717		Patients With Recurrent Ovarian Cancer After a Partial Response to the Last
718		Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial. J Clin Oncol
719		2019, 37 (32):2968-2973.

720	14.	González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza
721		MR, McCormick C, Lorusso D, Hoskins P, Freyer G et al: Niraparib in Patients
722		with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med 2019,
723		381 (25):2391-2402.
724	15.	Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M,
725		Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL et al: Veliparib with First-
726		Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. $N Engl J$
727		<i>Med</i> 2019, 381 (25):2403-2415.
728	16.	Ramalingam SS, Novello S, Guclu SZ, Bentsion D, Zvirbule Z, Szilasi M, Bernabe R,
729		Syrigos K, Byers LA, Clingan P et al: Veliparib in Combination With Platinum-
730		Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell
731		Lung Cancer: A Randomized, Multicenter Phase III Study. J Clin Oncol 2021,
732		39 (32):3633-3644.
733	17.	Creeden JF, Nanavaty NS, Einloth KR, Gillman CE, Stanbery L, Hamouda DM,
734		Dworkin L, Nemunaitis J: Homologous recombination proficiency in ovarian and
735		breast cancer patients. BMC Cancer 2021, 21(1):1154.
736	18.	Jette NR, Kumar M, Radhamani S, Arthur G, Goutam S, Yip S, Kolinsky M,
737		Williams GJ, Bose P, Lees-Miller SP: ATM-Deficient Cancers Provide New
738		Opportunities for Precision Oncology . Cancers (Basel) 2020, 12 (3).
739	19.	Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R, Syndikus I, Ralph C,
740		Jain S, Varughese M et al: Olaparib in patients with metastatic castration-
741		resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a
742		multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology 2020,
743		21 (1):162-174.

744	20.	Bang YJ, Xu RH, Chin K, Lee KW, Park SH, Rha SY, Shen L, Qin S, Xu N, Im SA
745		et al: Olaparib in combination with paclitaxel in patients with advanced gastric
746		cancer who have progressed following first-line therapy (GOLD): a double-
747		blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology 2017,
748		18 (12):1637-1651.
749	21.	Xie K, Ni X, Lv S, Zhou G, He H: Synergistic effects of olaparib combined with
750		ERCC1 on the sensitivity of cisplatin in non-small cell lung cancer. Oncol Lett
751		2021, 21 (5):365.
752	22.	Lok BH, Gardner EE, Schneeberger VE, Ni A, Desmeules P, Rekhtman N, De
753		Stanchina E, Teicher BA, Riaz N, Powell SN: PARP Inhibitor Activity Correlates
754		with SLFN11 Expression and Demonstrates Synergy with Temozolomide in
755		Small Cell Lung CancerSLFN11 Predicts PARP Inhibitor Response in SCLC.
756		<i>Clin Cancer Res</i> 2017, 23 (2):523-535.
757	23.	Allison Stewart C, Tong P, Cardnell RJ, Sen T, Li L, Gay CM, Masrorpour F, Fan Y,
758		Bara RO, Feng Y et al: Dynamic variations in epithelial-to-mesenchymal
759		transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and
760		cisplatin in small cell lung cancer. Oncotarget 2017, 8(17):28575-28587.
761	24.	Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, Ni A,
762		Khodos I, de Stanchina E, Nguyen T et al: Chemosensitive Relapse in Small Cell
763		Lung Cancer Proceeds through an EZH2-SLFN11 Axis. Cancer Cell 2017,
764		31 (2):286-299.
765	25.	Yusoh NA, Ahmad H, Gill MR: Combining PARP Inhibition with Platinum,
766		Ruthenium or Gold Complexes for Cancer Therapy. ChemMedChem 2020,
767		15 (22):2121-2135.

768	26.	Lu Y, Liu Y, Pang Y, Pacak K, Yang C: Double-barreled gun: Combination of
769		PARP inhibitor with conventional chemotherapy. Pharmacol Ther 2018, 188:168-
770		175.
771	27.	Dréan A, Lord CJ, Ashworth A: PARP inhibitor combination therapy. Crit Rev
772		Oncol/Hematol 2016, 108:73-85.
773	28.	Fankhauser M, Bechmann N, Lauseker M, Goncalves J, Favier J, Klink B, William D,
774		Gieldon L, Maurer J, Spöttl G et al: Synergistic Highly Potent Targeted Drug
775		Combinations in Different Pheochromocytoma Models Including Human Tumor
776		Cultures. Endocrinology 2019, 160(11):2600-2617.
777	29.	Cao X, Lu Y, Liu Y, Zhou Y, Song H, Zhang W, Davis D, Cui J, Hao S, Jung J et al:
778		Combination of PARP inhibitor and temozolomide to suppress chordoma
779		progression. Journal of Molecular Medicine 2019, 97(8):1183-1193.
780	30.	Shen H-Y, Tang H-L, Zheng Y-H, Feng J, Dong B-X, Chen X-Q: The PARP1
781		Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with
782		Temozolomide for Antimyeloma Effects . <i>Journal of oncology</i> 2022, 2022 :2800488.
783	31.	Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz
784		VD, Cox BF, DeWeese TL, Dillehay LE et al: ABT-888, an Orally Active
785		Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents
786		in Preclinical Tumor Models. Clin Cancer Res 2007, 13(9):2728-2737.
787	32.	Tentori L, Leonetti, C., Scarsella, M., Muzi, A., Mazzon, E., Vergati, M., Forini, O.,
788		Lapidus, R., Xu, W., Dorio, A.S., Zhang, J., Cuzzocrea, S. and Graziani, G.:
789		Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced
790		intestinal damage and enhances irinotecan/temozolomide efficacy against colon
791		carcinoma. The FASEB Journal 2006, 20 (10):1709-1711.

792	33.	Murai J, Zhang Y, Morris J, Ji J, Takeda S, Doroshow JH, Pommier Y: Rationale for
793		Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with
794		Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic
795		Inhibition. J Pharmacol Exp Ther 2014, 349 (3):408-416.
796	34.	Cardillo TM, Sharkey RM, Rossi DL, Arrojo R, Mostafa AA, Goldenberg DM:
797		Synthetic Lethality Exploitation by an Anti–Trop-2-SN-38 Antibody–Drug
798		Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2–wild-type Triple-
799		Negative Breast Cancer. Clin Cancer Res 2017, 23(13):3405-3415.
800	35.	Genther Williams SM, Kuznicki AM, Andrade P, Dolinski BM, Elbi C, O'Hagan RC,
801		Toniatti C: Treatment with the PARP inhibitor, niraparib, sensitizes colorectal
802		cancer cell lines to irinotecan regardless of MSI/MSS status. Cancer Cell
803		International 2015, 15 (1):14.
804	36.	Davidson D, Wang Y, Aloyz R, Panasci L: The PARP inhibitor ABT-888
805		synergizes irinotecan treatment of colon cancer cell lines. Invest New Drugs 2013,
806		31 (2):461-468.
807	37.	Tahara M, Inoue T, Sato F, Miyakura Y, Horie H, Yasuda Y, Fujii H, Kotake K,
808		Sugano K: The Use of Olaparib (AZD2281) Potentiates SN-38 Cytotoxicity in
809		Colon Cancer Cells by Indirect Inhibition of Rad51-Mediated Repair of DNA
810		Double-Strand Breaks. Mol Cancer Ther 2014, 13(5):1170-1180.
811	38.	Bowman KJ, Newell DR, Calvert AH, Curtin NJ: Differential effects of the poly
812		(ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II
813		inhibitor cytotoxicity in L1210 cells in vitro. Br J Cancer 2001, 84(1):106-112.
814	39.	Eetezadi S, Evans JC, Shen Y-T, De Souza R, Piquette-Miller M, Allen C: Ratio-
815		Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and
816		Spheroid Models of Ovarian Cancer. Mol Pharm 2018, 15(2):472-485.

817	40.	MIYAMOTO K, MINEGAKI T, TANAHASHI M, YAMAMOTO A, MORIYAMA
818		Y, WADA A, MATSUMOTO A, OTA K, TANAKA M, MASUDA U et al:
819		Synergistic Effects of Olaparib and DNA-damaging Agents in Oesophageal
820		Squamous Cell Carcinoma Cell Lines. Anticancer Res 2019, 39(4):1813-1820.
821	41.	Yanaihara N, Yoshino Y, Noguchi D, Tabata J, Takenaka M, Iida Y, Saito M,
822		Yanagida S, Iwamoto M, Kiyokawa T et al: Paclitaxel sensitizes homologous
823		recombination-proficient ovarian cancer cells to PARP inhibitor via the
824		CDK1/BRCA1 pathway. Gynecol Oncol 2022, 168:83-91.
825	42.	Shelton JW, Waxweiler TV, Landry J, Gao H, Xu Y, Wang L, El-Rayes B, Shu HK:
826		In vitro and in vivo enhancement of chemoradiation using the oral PARP
827		inhibitor ABT-888 in colorectal cancer cells. Int J Radiat Oncol Biol Phys 2013,
828		86 (3):469-476.
829	43.	Matulonis U, Monk B: PARP inhibitor and chemotherapy combination trials for
830		the treatment of advanced malignancies: does a development pathway forward
831		exist? Ann Oncol 2017, 28(3):443-447.
832	44.	Lefebvre C GJ, Briscoe S, Featherstone R, Littlewood A, Marshall C, Metzendorf M-
833		I, Noel-Storr A, Paynter R, Rader T, Thomas J, Wieland LS: Technical Supplement
834		to Chapter 4: Searching for and selecting studies. Cochrane Handbook for
835		Systematic Reviews of Interventions Version 63 (updated February 2022) 2022, In:
836		Higgins JPT, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, Welch VA
837		(eds).
838	45.	Liu YZ, Hodgson D, Locker G, Lai Z, Balcerzak D, Sharpe A, Barrett JC, Orr M,
839		Gutjahr TS, Dougherty B et al: Olaparib plus paclitaxel sensitivity in biomarker
840		subgroups of gastric cancer. Ann Oncol 2018, 29:25-26.

841	46.	Sharma P, Rodler E, Barlow WE, Gralow J, Huggins-Puhalla SL, Anders CK,
842		Goldstein LJ, Brown-Glaberman UA, Huynh TT, Szyarto CS et al: Results of a
843		phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative
844		breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG
845		S1416) . Journal of Clinical Oncology 2020, 38 (15).
846	47.	Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ,
847		Villalona-Calero MA, Morgan RJ, Jr., Szabo PM, Youn A et al: Randomized Trial
848		of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian,
849		Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian
850		Cancer. Clin Cancer Res 2015, 21(7):1574-1582.
851	48.	Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, Owonikoko
852		TK, Woo KM, Cardnell RJ, Fujimoto J et al: Randomized, Double-Blind, Phase II
853		Study of Temozolomide in Combination With Either Veliparib or Placebo in
854		Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J Clin
855		<i>Oncol</i> 2018, 36 (23):2386-2394.
856	49.	T T: A package for Survival Analysis in R. In., vol. R package version 3.3-1; 2022.
857	50.	Team RC: A Language and Environment for Statistical Computing. In. R
858		Foundation for Statistical Computing; 2021.
859	51.	Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ,
860		Cheng HY, Corbett MS, Eldridge SM et al: RoB 2: a revised tool for assessing risk
861		of bias in randomised trials. BMJ 2019, 366:14898.
862	52.	Swisher EM, Aghajanian C, O'Malley DM, Fleming GF, Kaufmann SH, Levine DA,
863		Birrer MJ, Moore KN, Spirtos NM, Shahin MS et al: Impact of homologous
864		recombination status and responses with veliparib combined with first-line

865 chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.

- 866 *Gynecol Oncol* 2022, **164**(2):245-253.
- 867 53. Byers LA, Bentsion D, Gans S, Penkov K, Son C, Sibille A, Owonikoko TK, Groen
- 868 HJM, Gay CM, Fujimoto J et al: Veliparib in combination with carboplatin and
- 869 etoposide in patients with treatment-Naive extensive-stage small cell lung cancer:
- 870 **A phase 2 randomized study**. *Clin Cancer Res* 2021, **27(14)**:3884-3895.
- 54. Geyer CE, Sikov WM, Huober J, Rugo HS, Wolmark N, O'Shaughnessy J, Maag D,
- 872 Untch M, Golshan M, Lorenzo JP *et al*: Long-term efficacy and safety of addition
- 873 of carboplatin with or without veliparib to standard neoadjuvant chemotherapy
- 874 in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a
- 875 **randomized phase III trial**. *Ann Oncol* 2022, **33**(4):384-394.
- 876 55. Middleton MR, Friedlander P, Hamid O, Daud A, Plummer R, Falotico N, Chyla B,
- Jiang F, McKeegan E, Mostafa NM *et al*: Randomized phase II study evaluating
- 878 veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
- 879 *Ann Oncol* 2015, **26**(10):2173-2179.
- 56. Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N,
- 881 Špaček J, Vuylsteke P, Hirte H *et al*: **Olaparib combined with chemotherapy for**
- 882 recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. *The*
- 883 *Lancet Oncology* 2015, **16**(1):87-97.
- 57. Diéras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL,
- 885 Bondarenko I, Campone M, Jakobsen EH et al: Veliparib with carboplatin and
- 886 paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a
- 887 randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet Oncology*
- 888 2020, **21**(10):1269-1282.

889	58.	Han HS, Diéras V, Robson M, Palácová M, Marcom PK, Jager A, Bondarenko I,
890		Citrin D, Campone M, Telli ML et al: Veliparib with temozolomide or
891		carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with
892		BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
893		Ann Oncol 2018, 29 (1):154-161.
894	59.	Llombart-Cussac A, Bermejo B, Villanueva C, Delaloge S, Morales S, Balmaña J,
895		Amillano K, Bonnefoi H, Casas A, Manso L et al: SOLTI NeoPARP: a phase II
896		randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel
897		alone as neoadjuvant therapy in patients with triple-negative breast cancer.
898		Breast Cancer Res Treat 2015, 154(2):351-357.
899	60.	Govindan R, Lind M, Insa A, Khan SA, Uskov D, Tafreshi A, Guclu S, Bar J, Kato T,
900		Lee KH et al: Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's
901		Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous
902		Non-Small Cell Lung Cancer. Clin Lung Cancer 2022, 23(3):214-225.
903	61.	O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman
903 904	61.	O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, Bradley C: Iniparib plus chemotherapy in metastatic triple-negative breast
903 904 905	61.	O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, Bradley C: Iniparib plus chemotherapy in metastatic triple-negative breast cancer. <i>N Engl J Med</i> 2011, 364 (3):205-214.
903 904 905 906	61.62.	O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, Bradley C: Iniparib plus chemotherapy in metastatic triple-negative breast cancer . <i>N Engl J Med</i> 2011, 364 (3):205-214. O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M,
 903 904 905 906 907 	61.62.	O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, Bradley C: Iniparib plus chemotherapy in metastatic triple-negative breast cancer . <i>N Engl J Med</i> 2011, 364 (3):205-214. O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, Robert N, Hellerstedt B, Saleh M, Richards P <i>et al</i> : Phase III study of iniparib plus
 903 904 905 906 907 908 	61.62.	O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, Bradley C: Iniparib plus chemotherapy in metastatic triple-negative breast cancer . <i>N Engl J Med</i> 2011, 364 (3):205-214. O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, Robert N, Hellerstedt B, Saleh M, Richards P <i>et al</i> : Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with
 903 904 905 906 907 908 909 	61.	O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, Bradley C: Iniparib plus chemotherapy in metastatic triple-negative breast cancer . <i>N Engl J Med</i> 2011, 364 (3):205-214. O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, Robert N, Hellerstedt B, Saleh M, Richards P <i>et al</i> : Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer . <i>J Clin Oncol</i> 2014, 32 (34):3840-3847.
 903 904 905 906 907 908 909 910 	61.62.63.	O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, Bradley C: Iniparib plus chemotherapy in metastatic triple-negative breast cancer . <i>N Engl J Med</i> 2011, 364 (3):205-214. O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, Robert N, Hellerstedt B, Saleh M, Richards P <i>et al</i> : Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer . <i>J Clin Oncol</i> 2014, 32 (34):3840-3847. Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry
 903 904 905 906 907 908 909 910 911 	61.62.63.	O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, Bradley C: Iniparib plus chemotherapy in metastatic triple-negative breast cancer . <i>N Engl J Med</i> 2011, 364 (3):205-214. O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, Robert N, Hellerstedt B, Saleh M, Richards P <i>et al</i> : Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer . <i>J Clin Oncol</i> 2014, 32 (34):3840-3847. Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM <i>et al</i> : Homologous Recombination Deficiency (HRD)

913		Patients with Triple-Negative Breast Cancer. Clin Cancer Res 2016, 22(15):3764-
914		3773.
915	64.	Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S,
916		Pommier Y: Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.
917		Cancer Res 2012, 72(21):5588-5599.
918	65.	Thomas A, Murai J, Pommier Y: The evolving landscape of predictive biomarkers
919		of response to PARP inhibitors. The Journal of Clinical Investigation 2018,
920		128 (5):1727-1730.
921	66.	Rudolph J, Jung K, Luger K: Inhibitors of PARP: Number crunching and
922		structure gazing. Proceedings of the National Academy of Sciences 2022,
923		119 (11):e2121979119.
924	67.	Leal TA, Sharifi MN, Chan N, Wesolowski R, Turk AA, Bruce JY, O'Regan RM,
925		Eickhoff J, Barroilhet LM, Malhotra J et al: A phase I study of talazoparib (BMN
926		673) combined with carboplatin and paclitaxel in patients with advanced solid
927		tumors (NCI9782). Cancer Medicine 2022, 11(21):3969-3981.
928	68.	Ngoi NYL, Tan DSP: The role of homologous recombination deficiency testing in
929		ovarian cancer and its clinical implications: do we need it? ESMO Open 2021,
930		6 (3):100144.
931	69.	Rempel E, Kluck K, Beck S, Ourailidis I, Kazdal D, Neumann O, Volckmar AL,
932		Kirchner M, Goldschmid H, Pfarr N et al: Pan-cancer analysis of genomic scar
933		patterns caused by homologous repair deficiency (HRD). npj Precision Oncology
934		2022, 6 (1):36.
935	70.	Mu Y, Lou J, Srivastava M, Zhao B, Feng X-h, Liu T, Chen J, Huang J: SLFN11
936		inhibits checkpoint maintenance and homologous recombination repair. EMBO
937		<i>Rep</i> 2016, 17 (1):94-109.

938	71.	Willis SE, Winkler C, Roudier MP, Baird T, Marco-Casanova P, Jones EV, Rowe P,
939		Rodriguez-Canales J, Angell HK, Ng FSL et al: Retrospective analysis of
940		Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA
941		damage response. Br J Cancer 2021, 125(12):1666-1676.
942	72.	Wang C, Li J: Haematologic toxicities with PARP inhibitors in cancer patients:
943		an up-to-date meta-analysis of 29 randomized controlled trials. J Clin Phar Ther
944		2021, 46 (3):571-584.
945	73.	Tookman L, Krell J, Nkolobe B, Burley L, McNeish IA: Practical guidance for the
946		management of side effects during rucaparib therapy in a multidisciplinary UK
947		setting. Therapeutic advances in medical oncology 2020, 12:1758835920921980-
948		1758835920921980.
949	74.	Lustberg MB: Management of neutropenia in cancer patients. Clin Adv Hematol
950		<i>Oncol</i> 2012, 10 (12):825-826.